Seres Therapeutics Files 8-K on Financial Condition Update

TL;DR

**Seres Therapeutics just dropped an 8-K on its financials, get ready for new numbers.**

AI Summary

Seres Therapeutics, Inc. (MCRB) filed an 8-K on January 10, 2024, reporting an event that occurred on January 9, 2024, related to its 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers a timely glimpse into the company's financial state, potentially influencing stock price and investment decisions.

Why It Matters

This filing signals that Seres Therapeutics is disclosing new financial information, which is vital for investors to assess the company's performance and make informed decisions about buying, holding, or selling its stock.

Risk Assessment

Risk Level: low — This 8-K filing is a routine disclosure of financial information, not an announcement of a negative event, thus posing a low immediate risk.

Analyst Insight

A smart investor would look for the actual financial statements and results of operations that this 8-K refers to, as this filing itself is merely a notification of an upcoming or concurrent disclosure of financial data. This will provide the specific numbers needed to evaluate Seres Therapeutics' performance.

Key Players & Entities

• Seres Therapeutics, Inc. (company) — the registrant filing the 8-K
• MCRB (company) — the trading symbol for Seres Therapeutics, Inc.
• The Nasdaq Stock Market LLC (Nasdaq Global Select Market) (company) — the exchange where Seres Therapeutics' common stock is registered
• January 9, 2024 (date) — the date of the earliest event reported in the 8-K
• January 10, 2024 (date) — the filing date of the 8-K

FAQ

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar
• $10.4 million — had net sales of VOWST of approximately $10.4 million (unaudited) in the fourth quarter of 20
• $128 million — alents and investments of approximately $128 million (unaudited) as of December 31, 2023. Th

Filing Documents

• d129973d8k.htm (8-K) — 31KB
• d129973dex991.htm (EX-99.1) — 27KB
• g129973g0110045634462.jpg (GRAPHIC) — 6KB
• 0001193125-24-005614.txt ( ) — 190KB
• mcrb-20240109.xsd (EX-101.SCH) — 3KB
• mcrb-20240109_lab.xml (EX-101.LAB) — 17KB
• mcrb-20240109_pre.xml (EX-101.PRE) — 11KB
• d129973d8k_htm.xml (XML) — 3KB

02

Item 2.02. Results of Operations and Financial Condition. On January 9, 2024, Seres Therapeutics, Inc. (the "Company") issued a press release in which the Company announced, among other things, that based on preliminary financial results, the Company had net sales of VOWST of approximately $10.4 million (unaudited) in the fourth quarter of 2023, and preliminary cash, cash equivalents and investments of approximately $128 million (unaudited) as of December 31, 2023. The full text of the press release was posted in the "Investors and News" portion of its website at www.serestherapeutics.com. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. These preliminary financial results are based on preliminary unaudited information and the Company's current estimate of its results for the year ended December 31, 2023, and remain subject to change based on the completion of closing and review procedures and the execution of the Company's internal control over financial reporting. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, these preliminary estimates. On January 9, 2024, the Company also posted an updated corporate presentation including the foregoing preliminary financial results in the "Investors and News" portion of its website at www.serestherapeutics.com, and intends to present the preliminary financial results at the 42 nd annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 12:45 p.m. Eastern Time / 9:45 a.m. Pacific Time. The live presentation and archived webcast will be accessible from the Company's website at www.serestherapeutics.com. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. The information in Item 2.02 of this Current Report on Form 8-K,

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including statements about the Company's anticipated financial results for the year ended December 31, 2023, the Company's attendance at any conferences, and the content of the information that the Company may present at conferences. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of unfavorable economic conditions; the completion of closing and review procedures and the execution of the Company's internal control of financial reporting; and other factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), on November 2, 2023, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report on Form 8-K. Any such forward-looking statements represent management's estimates as of the date of this Current Report on Form 8-K. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. The following Exhibits 99.1 and 99.2 relate to Item 2.02 and shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release, dated January 9, 2024 99.2 Seres Therapeutics, Inc. Corporate Presentation as of January 2024 (incorporated by reference to Exhibit 99.1 to the Company's Current Report on Form 8-K filed on January 9, 2024) 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 10, 2024 SERES THERAPEUTICS, INC. By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Chief Legal Officer and Executive Vice President

View Full Filing

View this 8-K filing on SEC EDGAR